Compare Eli Lilly And Co (LLY) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs J M Smucker Co — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while J M Smucker Co trades at $119.83 (market cap $12.76B). The key difference: Eli Lilly And Co is far larger — about 81.5× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.75%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and J M Smucker Co for 74 Days on average.
| LLY | SJM | |
|---|---|---|
Market Cap | $1.04T | $12.76B |
Volume | 3,064,878 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $132.34 |
52-Week Low | $799.57 | $89.53 |
Typical Hold Time | 93 Days | 74 Days |
Enterprise Value | $1.09T | $19.61B |
Dividend Yield | 0.59% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
SJM stock trades at $119.41, up 3.0% with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The company maintains strong cash flow from operations at $1.21B and recently raised FY27 EPS guidance to $10.50-$11.00. However, 2025 results showed a net loss of $1.23B despite $8.73B revenue, with elevated P/E ratio of 55.8 suggesting premium valuation.
Outlook remains cautiously optimistic with analyst consensus target of $138.23 (16% upside) and 52% buy ratings, though high debt levels and margin pressures present risks. The stock offers dividend income with upcoming $1.12 payment, while technical support at $118 provides near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
